Emmaus Life Sciences Financing
Emmaus Life Sciences, Inc., Corporation just released form D announcing $20.00 million equity financing. This is a new filing. Emmaus Life Sciences was able to fundraise $20.00 million. That is 100.00% of the financing offer. The total financing amount was $20.00 million. The offering form was filed on 2016-10-14. The reason for the financing was: We are paying a Korean based investment company, Nexpedia Consulting Co. Ltd., a finders fee..
Emmaus Life Sciences is based in California. The firm’s business is Pharmaceuticals. The D form was signed by Yutaka Niihara Chief Executive Officer. The company was incorporated more than five years ago. The filler’s address is: 21250 Hawthorne Boulevard, Suite 800, Torrance, Ca, California, 90503. Yutaka Niihara is the related person in the form and it has address: 21250 Hawthorne Boulevard, Suite 800, Torrance, Ca, California, 90503. Link to Emmaus Life Sciences Filing: 000110465916150324.
Analysis of Emmaus Life Sciences Offering
On average, firms in the Pharmaceuticals sector, sell 60.90% of the total offering amount. Emmaus Life Sciences sold 100.00% of the offering. Could this mean that the trust in Emmaus Life Sciences is high? The average investment floor size for companies in the Pharmaceuticals industry is $556,000. The total amount raised is 3,497.12% bigger than the average for companies in the Pharmaceuticals sector. The minimum investment for this financing is set at $0. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Emmaus Life Sciences Also
The Form D signed by Yutaka Niihara might help Emmaus Life Sciences, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.